EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD ‐ L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma

Kun Gao, Zhigong Wei, Zheran Liu iD, Yiyan Pei, Huilin Li, Ge Song, Jin Xiang, Junyou Ge, Yan Qing, Youneng Wei, Ping Ai iD, Ye Chen und 1 weitere

Head & Neck · 2025

DOI: 10.1002/hed.28101 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Kun Gao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head & Neck Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chen…. Hauptthemen laut MEDLINE: Neutrophils, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Xingchen Peng, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Regional Innovation and Development Joint Fund Key Project of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neutrophil‐to‐lymphocyte ratio (NLR) can be treated as a simple indicator of patients' immune status by representing the state of the systemic inflammatory response. Immunotherapy now is the accepted second‐line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). However, the significance of NLR in patients with R/M NPC undergoing treatment with PD‐L1 (programmed cell death‐ligand 1) inhibitors is still uncertain.

Methods

We analyzed the relationship between baseline NLR with 153 patients' efficacy and survival from a multicenter, prospective, Phase 2 study. We employed restricted cubic spline plots to get the nonlinear relationship between NLR and progression‐free survival (PFS) or overall survival (OS). We identified the ideal cut‐off value through the analysis of the receiver operating characteristic curve (ROC curve). We used Logistic regression, Cox regression, Log‐rank test, and Kaplan–Meier method to analyze the association between NLR and patients' disease control rate (DCR) and PFS or OS.

Results

The ideal threshold value for NLR was 2.826. NLR was identified as a significant independent predictor of DCR (OR = 0.17, 95% CI = 0.05–0.48, p = 0.001), indicating that a higher NLR is associated with worse DCR. NLR (AUC = 0.634) showed superior predictive capability for DCR in comparison to lymphocytes (AUC = 0.602) and neutrophils (AUC = 0.593). High NLR values were risk factors both for poor PFS (HR = 2.53, 95% CI = 1.58–4.06, p < 0.001) and OS (HR = 3.89, 95% CI = 2.09–7.24, p < 0.001).

Conclusion

Elevated NLR is strongly associated with lower response to treatment and reduced survival rates in patients with R/M NPC being treated with PD‐L1 inhibitors. Patients with high NLR values have poor efficacy and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsLymphocytesHumansMaleFemaleMiddle AgedAdultAgedProspective StudiesB7-H1 AntigenLymphocyte Count

Stichwörter der Autor:innen

PD‐L1 inhibitorimmunotherapyneutrophil‐to‐lymphocyte ratiorecurrent or metastatic nasopharyngeal carcinoma

Substanzen

Immune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Head & Neck Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Targeting Therapy & Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • West China Lecheng Hospital, Sichuan University, Chengdu, China.
  • Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd, Chengdu, China.
  • Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Zheran Liu, Ping Ai

Förderung

  • Xingchen Peng
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Regional Innovation and Development Joint Fund Key Project of the National Natural Science Foundation of China
  • National Natural Sciences Foundation of China
  • Sichuan Provincial Science and Technology Department Key Research and Development Program
  • Sichuan Science and Technology Program
  • Science and Technology Project of Sichuan Provincial Health Commission
  • International Science and Technology Cooperation Program of Chengdu Science and Technology Bureau

Zitieren

APA

Gao, K., Wei, Z., Liu, Z., Pei, Y., Li, H., Song, G., Xiang, J., Ge, J., Qing, Y., Wei, Y., Ai, P., Chen, Y., & Peng, X. (2025). Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD ‐ L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma. Head & Neck. https://doi.org/10.1002/hed.28101

Vancouver

Gao K, Wei Z, Liu Z, Pei Y, Li H, Song G, et al. Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD ‐ L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma. Head & Neck. 2025. doi:10.1002/hed.28101

BibTeX
@article{Gao2025,
  author = {Gao, Kun and Wei, Zhigong and Liu, Zheran and Pei, Yiyan and Li, Huilin and Song, Ge and Xiang, Jin and Ge, Junyou and Qing, Yan and Wei, Youneng and Ai, Ping and Chen, Ye and Peng, Xingchen},
  title = {Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD ‐ L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.28101}
}
Kostenlos starten →